MediWound to Report First Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern TimeYAVNE, Israel, May 12, 2023 (GLOBE NEWSWIRE)...
Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern TimeYAVNE, Israel, May 12, 2023 (GLOBE NEWSWIRE)...
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in...
Showcase to feature presentations by key opinion leaders Drs. Gaël Roué and Bhavana Pothuri Showcase to take place on May...
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the...
HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and...
Six Upcoming Presentations at the Annual Meetings of the American Society of Gene and Cell Therapy (ASGCT) and of the...
OREM, Utah, May 12, 2023 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (OTCQB: RSCF), a provider of diverse products and services...
Presented positive INB-100 data showing long-term complete remissions (CR) and elevated gamma-delta T cell levels in 100% of evaluable treated...
MONTREAL, May 12, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines...
New Trial Sites Enroll 60% of New Patient Enrollments Since the Beginning of April Tigris Patient Enrollment at 58 Patients...
-- New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential...
SCYNEXIS is receiving an upfront payment of $90 million with future performance-based milestone payments of up to $503 million and...
CHERRY HILL, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a...
SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that...
Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson’s diseaseCompany is on track to submit application for...
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash...
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update Capital Markets Day held in April highlighted...
Dr. Rachel Yehuda to Lead Discussions on Therapeutic Application of Psychedelics Additional Featured Speakers Include Dr. Julie Holland, Dr. Carl...
Record first quarter 2023 consolidated revenue of $33.1 million, up 14% from the same year-ago period.Record Adjusted EPS of $0.06...
- Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma - - Completion of enrollment...